FIELD: medicine.
SUBSTANCE: group of inventions refers to an antibody or its antigen-binding fragment, which specifically bind to human OX40L (hOX40L) and inhibit binding of hOX40L to human OX40 (hOX40). Group of inventions also relates to use of said antibody in producing a drug for treating or preventing OX40L-mediated disease or condition; a method of treating or preventing an OX40L-mediated disease or condition in a subject, comprising administering to a human a therapeutically effective amount of said antibody or fragment thereof; combination for treating or preventing an hOX40L-mediated disease or condition containing said antibody or antigen-binding fragment thereof and an additional therapeutic agent, selected from an mTOR inhibitor and an immunosuppressant which modulates IL-2 signaling; kit for treating or preventing hOX40L-mediated disease or condition in humans.
EFFECT: group of inventions provides treating or preventing the hOX40L-mediated disease or condition in humans.
33 cl, 9 ex, 7 dwg, 6 tbl
Title | Year | Author | Number |
---|---|---|---|
ANTI-OX40 ANTIBODIES AND THEIR APPLICATION | 2017 |
|
RU2753493C2 |
COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
BISPECIFIC FUSION PROTEIN AND ITS USE | 2021 |
|
RU2801528C2 |
ANTI-CEACAM1 ANTIBODY AND ITS APPLICATION | 2018 |
|
RU2754876C2 |
ANTIGEN-BINDING PROTEINS AGAINST TIGIT AND THEIR APPLICATION METHODS | 2018 |
|
RU2776714C2 |
BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
ANTIBODIES TO PAC1 AND THEIR APPLICATION OPTIONS | 2019 |
|
RU2781553C2 |
ANTIBODIES B7-H4 AND METHODS FOR THEIR APPLICATION | 2019 |
|
RU2809243C2 |
NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
C5 ANTIBODIES AND THEIR APPLICATION METHODS | 2015 |
|
RU2746356C2 |
Authors
Dates
2020-06-30—Published
2016-03-03—Filed